Xeris Biopharma Holdings, Inc. revised revenue guidance for the year 2023. For the year, the company expects to report total revenue at the high end of its previous guidance of $160 million to $165 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.355 USD | +0.64% |
|
+11.61% | +0.21% |
Jul. 08 | Xeris Biopharma Appoints John Shannon as CEO | MT |
Jul. 08 | Xeris Biopharma Holdings, Inc. Announces CEO Changes | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.21% | 349M | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Year 2023